Funding Opportunity PA-25-302 from the NIH Guide for Grants and Contracts. The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Notice of Funding Opportunity does not accept applications proposing clinical trial(s).

Funding Opportunity RFA-DK-26-006 from the NIH Guide for Grants and Contracts. The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.

Notice NOT-AG-24-093 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-032 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

Notice NOT-DC-25-021 from the NIH Guide for Grants and Contracts

Notice NOT-HG-25-017 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-315 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research to elucidate how HIV-induced immunometabolic alterations, in a host suppressed on combination antiretroviral therapy (cART-suppressed), impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection such as Mycobacterium tuberculosis (Mtb) or hepatitis B virus (HBV). This NOFO aims to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, tuberculosis (TB) and HBV disease progression.

Funding Opportunity PAR-25-316 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research to elucidate how HIV-induced immunometabolic alterations, in a host suppressed on combination antiretroviral therapy (cART-suppressed), impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection such as Mycobacterium tuberculosis (Mtb) or Hepatitis B Virus (HBV). This NOFO aims to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, Tuberculosis (TB) and HBV disease progression.

Notice NOT-OD-25-043 from the NIH Guide for Grants and Contracts

Notice NOT-HS-25-011 from the NIH Guide for Grants and Contracts

Notice NOT-HS-25-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-327 from the NIH Guide for Grants and Contracts. The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

Funding Opportunity PAR-25-326 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

Funding Opportunity RFA-DA-25-078 from the NIH Guide for Grants and Contracts. This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY25, this currently includes the Workforce NOSI, the Exposure to Violence NOSI, and the Leveraging Inpatient Hospitalizations NOSI. It has a companion R33 RFA.

Funding Opportunity RFA-DA-25-077 from the NIH Guide for Grants and Contracts. This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY25, this currently includes the Workforce NOSI, the Exposure to Violence NOSI, and the Leveraging Inpatient Hospitalizations NOSI. It has a companion R61/R33 RFA.

Notice NOT-NS-25-012 from the NIH Guide for Grants and Contracts

Notice NOT-GM-25-015 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-046 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-050 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-047 from the NIH Guide for Grants and Contracts